SkyWater and NanoDx™ Partner to Develop and Produce Nanoscale Sensors for Rapid COVID-19 Testing and Other Vital Diagnostics
Retrieved on:
Wednesday, October 6, 2021
Other Manufacturing, Technology, Medical Devices, Infectious Diseases, Semiconductor, FDA, Other Technology, Manufacturing, Hardware, Health, ISO, ICS, DOD, Research, IBM cloud computing, Harvard University, Diagnosis, Infection, Stroke, IBM Research, Private Securities Litigation Reform Act, NASDAQ, SkyWater Technology, CMOS, Patient, AGC Aerospace & Defense, Sepsis, Biomarker, IP, CEO, COVID-19 testing, Nanowire, Company, Emergency Use Authorization, IOT, TBI, Disease, COVID-19, Technology, Traumatic brain injury, Forward-looking statement, Medical device, Prospectus, MEMS, SEC, Pharmaceutical industry, Medical imaging, NanoDx, Inc., SkyWater Technology, NANODX, INC., SKYWATER TECHNOLOGY
NanoDx is partnering with SkyWater to scale the product and plans to pursue an Emergency Use Authorization from the U.S. FDA for rapid, two-minute, point-of-care COVID-19 testing.
Key Points:
- NanoDx is partnering with SkyWater to scale the product and plans to pursue an Emergency Use Authorization from the U.S. FDA for rapid, two-minute, point-of-care COVID-19 testing.
- NanoDx is planning to commercialize a real-time, point-of-care diagnostics platform capable of detecting and quantifying biomarkers (analytes) from a small fluid specimen.
- The breakthrough science integrated into the NanoDx System was originally based upon the revolutionary work of Harvard University, a pioneer of nanoscale technology.
- We are very pleased to work with NanoDx on this opportunity to potentially help early diagnosis of COVID-19 through rapid testing, said Thomas Sonderman, SkyWater president and CEO.